Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
about
Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysisModulation of Autophagy by Sorafenib: Effects on Treatment ResponseHeterogeneity of epidermal growth factor receptor signalling networks in glioblastomaUtilizing the Dog Genome in the Search for Novel Candidate Genes Involved in Glioma Development-Genome Wide Association Mapping followed by Targeted Massive Parallel Sequencing Identifies a Strongly Associated Locus.Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer.Metformin therapy associated with survival benefit in lung cancer patients with diabetesMetformin, an old drug, brings a new era to cancer therapyCombinational strategies of metformin and chemotherapy in cancers.Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies.Progress in the application and mechanism of metformin in treating non-small cell lung cancer.Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib.AMP-activated protein kinase - not just an energy sensor.The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors.Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS- Mutant Cancers.Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation.The Effects of Pycnogenol® as Add-on Drug to Metformin Therapy in Diabetic Rats.Anti-tumoral effects of exercise on hepatocellular carcinoma growth.Synergistic effect of metformin on sorafenib in study using hepatocellular carcinoma cell lines
P2860
Q26738743-014947BC-6199-4E0A-9192-C2A079D75B82Q26745320-B9904C9A-83EB-4F0D-AECE-EA7D9D9BD860Q27013006-7EAC03DC-3267-474E-BB94-A73D5B43DDF3Q36015724-3E01B04A-0455-4947-B4E6-4277B775B604Q36103093-AECE82F2-A6CA-44DE-AC77-0D9D31FDE774Q37376577-0E9465F5-A6BC-4AB1-9202-3882B12D48D1Q38393435-5F8BDB54-75CA-475E-92BD-3E04AA990973Q38818730-30727505-6876-43CE-973E-8A8F7CA617B5Q38819571-6DDD76D1-430E-4853-A887-5867CB51DE12Q39290525-1759597B-93AF-4D71-A483-F3EDC7BD61CBQ39321321-620D9CC3-038E-4F07-81AF-A8636B2D639CQ40380730-927F854D-2138-4E81-9E88-FD800437DA9AQ41095164-DE5DEF46-3C94-4524-84B8-3E880060D885Q42364792-61A014F2-5072-45B7-8099-461958D2E408Q47103987-FCA7F6BF-7F85-4240-A3D5-25204D3864E3Q48583910-C3A31696-324F-4165-85CB-8711F03690BEQ48597130-3B7BA20E-D03D-4183-9957-EE70227BEAD0Q53101458-B3AD2CB1-E7E3-48FD-81A6-2B6F5FEDF48CQ54979103-ED7154BD-AA4F-4798-A7A0-5926DFB48AD3Q58781345-917724BD-670F-460B-8D88-873B4AE7940B
P2860
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
@ast
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
@en
type
label
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
@ast
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
@en
prefLabel
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
@ast
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
@en
P2093
P2860
P356
P1476
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
@en
P2093
Egbert F Smit
Eline van der Burg
Floris H Groenendijk
Hugo M Horlings
Jos Jonkers
Michel M van den Heuvel
René Bernards
Stefan M Willems
Wouter W Mellema
P2860
P304
P356
10.1002/IJC.29113
P577
2014-08-08T00:00:00Z